Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class I · High risk Terminated Initiated Oct 21, 2013 (13 years ago)

Human Chorionic Gonadotropin

Class I — High risk. Reasonable probability of serious harm or death.

Why it was recalled

Labeling: Label Error on Declared Strength; Firm states that erroneous potency information was found on the label.

Cause type: Labeling / mix-up

Wrong label, wrong strength, mixed-up products, or packaging errors. One of the most dangerous causes - you can end up taking the wrong drug or the wrong dose. All labeling / mix-up recalls.

What was recalled

Human Chorionic Gonadotropin, EP (HCG) in 5 mu. 2 mu, and 1 mu packages, For use and distribution in prescription compounding, manufacturing, processing or repacking only in accordance with FDA regulations and applicable law. Potency 5489.6IU/mg. Packed by Medisca, Inc. Irving, TX, 75063, USA NDC 38779-2673-1, NDC 38779-2673-2, and NDC 38779-2673-6. Lot Numbers 101751/A, Exp: 05/16, CAS: 9002-61-3; 101752/A, Exp: 05/16, CAS 9002-61-3; and 101799/A, Exp: 05/16, CAS: 9002-61-3

Affected NDCs 38779-2673-01 38779-2673-02 38779-2673-06

Compare with the code on your package — it is the most precise check available.

Recalling firm
Medisca Inc.
NDC code
38779-2673-1
Origin
TX, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1263-2014 · FDA notice

Treat this as urgent. Class I means FDA judged there is a reasonable probability of serious harm. Find the lot number on your package; if it matches the recalled lots, do not take another dose before you have spoken to your pharmacist or prescriber - today, not next week. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other recalls by Medisca Inc.

All 2013 recalls
Class II · Moderate risk

Estriol

Failed Impurities/Degradation Specifications

Terminated Impurity / degradation Medisca, Inc. D-0622-2020
Class II · Moderate risk

Aminocaproic Acid

CGMP Deviations: Product manufactured for Industrial Use but was labeled and distributed for Pharmacy Compounding Use.

Terminated Labeling / mix-up Medisca, Inc. NDC 38779-0989-05 D-1174-2017

Other labeling / mix-up recalls from 2013

All labeling / mix-up recalls
Class II · Moderate risk

Trelstar (triptorelin pamoate)

Labeling: Label Error On Declared Strength: Trelstar 11.25 mg labeled carton/kit contained a vial labeled as 3.75 mg instead of a vial being labeled as 11.25mg.

Terminated Labeling / mix-up Actavis Inc NDC 52544-154-02 D-1085-2014
Class II · Moderate risk

0.45% Sodium Chloride Injection USP

Labeling: Wrong Bar Code; Bar code scans as 0.15% Potassium Chloride in 0.9% Sodium Chloride (20 mEq K/liter).

Terminated Labeling / mix-up B. Braun Medical Inc NDC 0264-7802-00 D-407-2014
Class III · Low risk

Paclitaxel Injection

Labeling: Incorrect or Missing Package Insert- Missing text on the product insert in the "Clinical Studies" and "Specific Adverse Events" sections.

Terminated Labeling / mix-up Fresenius Kabi USA, LLC NDC 63323-763-50 D-016-2014
Class II · Moderate risk

Carbon Dioxide

Labeling: Not Elsewhere Classified; Due to an error in the manufacturing procedure, a cylinder in liquid withdrawal service was not marked Syphon Tube indicating liquid withdrawal and shipped as a gas withdrawal cylinder.

Terminated Labeling / mix-up Airgas Medical Services D-366-2014